Search Results

You are looking at 1 - 10 of 21 items for :

  • "dopamine agonists" x
Clear All
Open access

Sarah Byberg, Jesper Futtrup, Mikkel Andreassen and Jesper Krogh

the metabolic effects of dopamine agonist treatment in patients with prolactinomas. Methods Study design A systematic review and meta-analysis. The study was registered with PROSPERO (registration number CRD42016046525). Study

Open access

Anastasia P Athanasoulia-Kaspar, Kathrin H Popp and Gunter Karl Stalla

Introduction Case report To emphasize the possible role of dopamine agonists in the development of impulse control disorders that could be potentially devastating for the patient’s life, we report a case of a giant-prolactinoma in a young

Open access

G Giuffrida, F Ferraù, R Laudicella, O R Cotta, E Messina, F Granata, F F Angileri, A Vento, A Alibrandi, S Baldari and S Cannavò

In aggressive pituitary tumors (PT) showing local invasion or growth/recurrence despite multimodal conventional treatment, temozolomide (TMZ) is considered a further therapeutic option, while little data are available on peptide receptor radionuclide therapy (PRRT). We analyzed PRRT effectiveness, safety and long-term outcome in three patients with aggressive PT, also reviewing the current literature. Patient #1 (F, giant prolactinoma) received five cycles (total dose 37 GBq) of 111In-DTPA-octreotide over 23 months, after unsuccessful surgery and long-term dopamine-agonist treatment. Patient #2 (M, giant prolactinoma) underwent two cycles (12.6 GBq) of 177Lu-DOTATOC after multiple surgeries, radiosurgery and TMZ. In patient #3 (F, non-functioning PT), five cycles (29.8 GBq) of 177Lu-DOTATOC followed five surgeries, radiotherapy and TMZ. Eleven more cases of PRRT-treated aggressive PT emerged from literature. Patient #1 showed tumor shrinkage and visual/neurological amelioration over 8-year follow-up, while the other PTs continued to grow causing blindness and neuro-cognitive disorders (patient #2) or monolateral amaurosis (patient #3). No adverse effects were reported. Including the patients from literature, 4/13 presented tumor shrinkage and clinical/biochemical improvement after PRRT. Response did not correlate with patients’ gender or age, neither with used radionuclide/peptide, but PRRT failure was significantly associated with previous TMZ treatment. Overall, adverse effects occurred only in two patients. PRRT was successful in 1/3 of patients with aggressive PT, and in 4/5 of those not previously treated with TMZ, representing a safe option after unsuccessful multimodal treatment. However, at present, considering the few data, PRRT should be considered only in an experimental setting.

Open access

Ali Abbara, Sophie Clarke, Pei Chia Eng, James Milburn, Devavrata Joshi, Alexander N Comninos, Rozana Ramli, Amrish Mehta, Brynmor Jones, Florian Wernig, Ramesh Nair, Nigel Mendoza, Amir H Sam, Emma Hatfield, Karim Meeran, Waljit S Dhillo and Niamh M Martin

4/52  Antiplatelet or anticoagulant 3/52  Dopamine agonists 2/52  Radiotherapy 2/52  None 24/52 Type of secretion of adenoma defined clinically or biochemically  NF or GT 47/52  PRL 5

Open access

Enrique Soto-Pedre, Paul J Newey, John S Bevan and Graham P Leese

hyperprolactinaemia may be associated with heart valve disease (including that related to the use of dopamine agonist therapy), cardiovascular risk factors or cardiovascular mortality ( 4 , 5 , 6 , 7 ). Results from epidemiologic studies that have examined the

Open access

Mikkel Andreassen, Anders Juul, Ulla Feldt-Rasmussen and Niels Jørgensen

reversible hypogonadism, and the effect of dopamine agonist treatment ( 8 , 9 , 10 , 11 , 12 ). There are in vitro , as well as clinical data, suggesting that prolactin per se affects male reproductive tissue in addition to the well-known suppressive

Open access

Julie M Silverstein

consensus criteria also established, for the first time, that a composite endpoint should be used for the monitoring of active acromegaly ( Fig. 1 ). Figure 1 Guidelines and recommendations for improvement in monitoring ( 1, 15, 26 ). DA, dopamine agonist

Open access

L Bahler, H J Verberne, E Brakema, R Tepaske, J Booij, J B Hoekstra and F Holleman

. References 1 American Diabetes Association. Standards of medical care in diabetes – 2008. Diabetes Care 2008 31 (Supplement 1) S12 – S54 . ( doi:10.2337/dbib8-s012 ) 2 Tan EK Jankovic J. Choosing dopamine agonists in Parkinson’s disease

Open access

Cecilia Follin and Sven Karlsson

surgery necessitates chronic medical treatment. Current medical therapies available to treat acromegaly consist of somatostatin analogues (SSAs) and dopamine agonist (DA) medication, both of which act to suppress GH secretion from pituitary adenomas or

Open access

A V Dreval, I V Trigolosova, I V Misnikova, Y A Kovalyova, R S Tishenina, I A Barsukov, A V Vinogradova and B H R Wolffenbuttel

( n =25). GH overproduction was controlled in 28 of the 97 individuals. None of the patients were treated with a dopamine agonist or with pegvisomant. Table 1 Comparative characteristics of patients with acromegaly and matched participants from the